Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: Analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology

Annals of Oncology

Volumn 23, Issue 7, 2012, Pages 1730-1738

  Jalal, S I ^a,b   Riggs, H D ^a,b   Melnyk, A ^c   Richards, D ^d   Agarwala, A ^e   Neubauer, M ^f   Ansari, R ^g   Govindan, R ^h   Bruetman, D ⁱ   Fisher, W ^j   Breen, T ^a,k   Johnson, C S ^a,k   Yu, M ^a,k   Einhorn, L ^a,b   Hanna, N ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c Texas Cancer Center Abilene   (United States)

^d Tyler Cancer Center   (United States)

^e INDIANA UNIVERSITY HEALTH   (United States)

^f Kansas City Cancer Center   (United States)

^g Northern Indiana Cancer Research Consortium   (United States)

^h UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

ⁱ Goshen Center for Cancer Care   (United States)

^j BALL MEMORIAL HOSPITAL   (United States)

^k Hoosier Oncology Group   (United States)

more..

Author keywords

Consolidation docetaxel; Elderly; Stage III lung cancer

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE;

ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DEHYDRATION; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION HAZARD; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE DISORDER;

EID: 84864310080     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr565     Document Type: Article

References (43)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Morgensztern D, Ng S, Gao F et al. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J thorac Oncol 2010; 5: 29-33.
3. Dillman R, Herndon J, Seagren S et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88: 1210-1215.
4. Schaake-Koning C, van den Bogaert W, Dalesio O et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326: 524-530.
5. Sause W, Kolesar P, Taylor S, IV et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117: 358-364.
6. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-2699.
7. Curran W, Jr, Paulus R, Langer C et al. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011; 103: 1452-1460.
8. Zatloukal P, Petruzelka L, Zemanova M et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004; 46: 87-98.
9. Fournel P, Robinet G, thomas P et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005; 23: 5910-5917.
10. Hanna N, Neubauer M, Yiannoutsos C et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26: 5755-5760.
11. Subramanian J, Morgensztern D, Goodgame B et al. Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. J thorac Oncol 2010; 5: 23-28.
12. Pritchard R, Anthony S Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-smallcell lung cancer. A meta-analysis. Ann Intern Med 1996; 125: 723-729.
13. Marino P, Preatoni A, Cantoni A Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 1995; 76: 593-601.
14. Fietkau R Stage-III NSCLC: multimodality therapy for inoperable tumours. Lung Cancer 2004; 45: S113-S123.
15. Movsas B, Scott C, Sause W et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 1999; 45: 1143-1149.
16. Langer C, Scott C, Byhardt R et al. Effect of advanced age on outcome in Radiation therapy Oncology Group studies of locally advanced NSCLC (LANSCLC). Lung Cancer 2000; 29: 104 (Abstr 340).
17. Werner-Wasik M, Scott C, Cox J et al. Recursive partitioning analysis of 1999 Radiation therapy Oncology Group (RTOG) patients with locally-advanced nonsmall-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000; 48: 1475-1482.
18. Langer C, Hsu C, Curran W et al. Elderly patients ( pts) with locally advanced non-small cell lung cancer (LA-NSCLC) benefit from combined modality therapy: secondary analysis of Radiation therapy Oncology Group (RTOG) 94-10. Proc Am Soc Clin Oncol 2002; 21: 299a (Abstr 1193).
19. Rocha Lima C, Herndon J, II, Kosty M et al. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 2002; 94: 181-187.
20. Schild S, Mandrekar S, Jatoi A et al. The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer 2007; 110: 363-368.
21. Schild S, Stella P, Geyer S et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 2003; 21: 3201-3206.
22. Barriger R, Fakiris A, Hanna N et al. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel. Int J Radiat Oncol Biol Phys 2010; 78: 1381-1386.
23. Ademuyiwa F, Johnson C, White A et al. Prognostic factors in stage III nonsmall-cell lung cancer. Clin Lung Cancer 2007; 8: 478-482.
24. Gandara D, Chansky K, Albain K et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21: 2004-2010.
25. Carter D, Keller A, Tolley R et al. A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by either weekly paclitaxel or observation in patients with stage III non-small cell lung cancer. J Clin Oncol 2004; 22: (Abstr 7076).
26. Park K, Ahn Y, Chen M et al. A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CCheIN): interim analysis. J Clin Oncol 2009; 27(Abstr 7538).
27. Kim Y, Choi E, Lee J et al. Consolidation chemotherapy with monthly paclitaxel and cisplatin (PC) or observation after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLC): randomized phase II study: PD4-1-7. J thorac Oncol 2007; 2: S449-S450.
28. Coate L, Massey C, Hope A et al. Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. J thorac Oncol 2011; 6: 537-544.
29. Lau D, Crowley J, Gandara D et al. Southwest Oncology Group Phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-smallcell lung cancer. J Clin Oncol 1998; 16: 3078-3081.
30. Belani C, Choy H, Bonomi P et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005; 23: 5883-5891.
31. Jatoi A, Schild S, Foster N et al. A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-smallcell lung cancer (N0422). Ann Oncol 2010; 21: 2040-2044.
32. Hutchins L, Unger J, Crowley J et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-2067.
33. Murthy V, Krumholz H, Gross C Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291: 2720-2726.
34. Marcantonio E, Aneja J, Jones R et al. Maximizing clinical research participation in vulnerable older persons: identification of barriers and motivators. J Am Geriatr Soc 2008; 56: 1522-1527.
35. Townsley C, Selby R, Siu L Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005; 23: 3112-3124.
36. Goodwin J, Hunt W, Samet J et al. Determinants of cancer therapy in elderly patients. Cancer 1993; 72: 594-601.
37. Jatoi A, Hillman S, Stella P et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 2005; 23: 9113-9119.
38. Atagi S, Kawahara M, Tamura T et al. Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol 2005; 35: 195-201.
39. Benson A, III, Pregler J, Bean J et al. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J Clin Oncol 1991; 9(11): 2067-2075.
40. Firat S, Pleister A, Byhardt R et al. Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC). Am J Clin Oncol 2006; 29: 252-257.
41. Semrau S, Klautke G, Virchow J et al. Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy. Respir Med 2008; 102: 210-218.
42. Hurria A, Togawa K, Mohile S et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective 500 patient multicenter study. J Clin Oncol 2010; 28 (Suppl): (Abstr 9001).
43. Hurria A, Cirrincione C, Muss H et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol 2011; 29: 1290-1296.